SUBSCRIBE
SUBSCRIBE
Pharm Country

No Exercise Benefit with Bosentan in Systemic Sclerosis, University of Connecticut Study

July 12, 2010 | 
1 min read

MedPage Today -- Treatment with the endothelin receptor antagonist bosentan (Tracleer) failed to improve exercise capacity in patients with systemic sclerosis, a randomized trial found.

MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Mother covering her face, experiencing depression symptoms
Drug Development
Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial
May 3, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Business
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
April 29, 2024
 · 
2 min read
 · 
Tyler Patchen